ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in the development of cell therapies for corneal blindness
18 Jan 2024
ERS Genomics Limited (ERS), the CRISPR licensing company which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and StemSight Oy (StemSight), a biotechnology company developing stem cell based therapies for corneal blindness, have announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patented portfolio.
ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs. With 89 patents held in over 90 countries, ERS Genomics licenses these patents via its direct license from Dr. Charpentier and now has nearly 150 licenses in place worldwide.